MP92-12 ANTI-ANDROGEN THERAPY SUPPRESSES TUMOR GROWTH IN ANDROGEN RECEPTOR-POSITIVE RENAL CELL CARCINOMA: A XENOGRAFT STUDY

Abstract

You have accessJournal of UrologyKidney Cancer: Basic Research & Pathophysiology III1 Apr 2016MP92-12 ANTI-ANDROGEN THERAPY SUPPRESSES TUMOR GROWTH IN ANDROGEN RECEPTOR-POSITIVE RENAL CELL CARCINOMA: A XENOGRAFT STUDY Christopher Han, Geun Taek Lee, Rutveej Patel, Parth Modi, Seok Joo Kwon, Izak Faiena, Neal Patel, Eric Singer, and Isaac Kim Christopher HanChristopher Han More articles by this author , Geun Taek LeeGeun Taek Lee More articles by this author , Rutveej PatelRutveej Patel More articles by this author , Parth ModiParth Modi More articles by this author , Seok Joo KwonSeok Joo Kwon More articles by this author , Izak FaienaIzak Faiena More articles by this author , Neal PatelNeal Patel More articles by this author , Eric SingerEric Singer More articles by this author , and Isaac KimIsaac Kim More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2645AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The presence of androgen receptor (AR) in renal cell carcinoma (RCC) has been shown to be associated with higher tumor stage irrespective of gender. Our previous study with androgen treatment in AR-positive RCC cell lines has resulted in tumor proliferation while enzalutamide (Enz) treatment caused reduction in cell viability. We have, therefore, performed a xenograft study to study the in vivo effect of anti-androgen therapy in AR-positive RCC. METHODS Male nude mice were randomly assigned to the castration and non-castration groups following the subcutaneous injection of an AR-positive RCC cell line, CAKI2. After surgical castration of the castration group, each group was further divided into six experimental arms: the main control arm without any treatment nor vehicle administration, the treatment arms with Enz, abiraterone acetate (AA), or the combination of Enz and AA treatments, and the respective vehicle-only arms for the Enz and AA arms. Both groups were treated for three weeks. RESULTS The castration group showed almost 40% reduction in the average tumor size compared to the non-castration group at three weeks (p<0.01). Compared to the respective vehicle-only arm, Enz arm showed 4- and 20-fold reductions in tumor sizes in the castration and non-castration groups, respectively (p<0.01). AA arm also showed 2.5- and 9-fold size reductions in each group, respectively (p<0.01). Furthermore, the combination therapy with Enz and AA showed 12- and 23-fold reductions, respectively, in tumor sizes compared to the main control arm (p<0.01). CONCLUSIONS Anti-androgen therapy suppresses tumor growth in AR-positive RCC in a xenograft model suggesting AR as a new potential target of intervention in the treatment of AR-positive RCC. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e1166 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Christopher Han More articles by this author Geun Taek Lee More articles by this author Rutveej Patel More articles by this author Parth Modi More articles by this author Seok Joo Kwon More articles by this author Izak Faiena More articles by this author Neal Patel More articles by this author Eric Singer More articles by this author Isaac Kim More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...